Celon Pharma

8 articles about Celon Pharma

• Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

  6/22/2021

  Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2 diabetes.

• Celon Pharma Hosting a Virtual Capital Markets Day on Wednesday, April 21st

  4/19/2021

  Celon Pharma S.A. announced that it will host a virtual Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET.

• Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial

  4/1/2021

  Celon Pharma S.A. announced the successful completion of a Phase 1 trial of its second generation GPR40 agonist, CPL’280.

• 

  Clinical Catch-Up: February 8-12

  2/15/2021

  It was a busy week for clinical trial announcements and news. Here’s a look.

• Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

  2/10/2021

  Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116.

• Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

  1/8/2021

  Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total score compared to placebo at Week 2 in all tested doses, with a dose-response trend. MADRS placebo-subtracted differences were -5.9 (95%

• Celon Pharma's Warsaw Stock Exchange IPO

  10/21/2016

• Celon Pharma Had The Largest IPO On The Polish Capital Market In 2016

  9/26/2016